Study summary

Sparsentan also lowered proteinuria in genetic forms of FSGS

DUPLEX genetic FSGS analysis · 70 people with genetic FSGS · Published April 2026, Clinical Journal of the American Society of Nephrology

What was tested

A post hoc analysis of DUPLEX in people with FSGS caused by podocyte gene variants, COL4A3-5 variants or high-risk APOL1 genotypes.

What they found

What it means

Suggests a role for sparsentan where immune drugs do not help.

Clin J Am Soc Nephrol, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.